Cargando…

Erratum to: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment

Detalles Bibliográficos
Autores principales:	Kampmann, Christoph, Perrin, Amandine, Beck, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941032/ https://www.ncbi.nlm.nih.gov/pubmed/27406229 http://dx.doi.org/10.1186/s13023-016-0482-3

Ejemplares similares

Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
por: Kampmann, Christoph, et al.
Publicado: (2015)

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
por: Beck, Michael, et al.
Publicado: (2015)

Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis
por: Ramaswami, Uma, et al.
Publicado: (2019)

Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events
por: Beck, Michael, et al.
Publicado: (2017)

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
por: Arends, Maarten, et al.
Publicado: (2018)

Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
por: Pisani, Antonio, et al.
Publicado: (2015)

Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients
por: Tsuboi, Kazuya, et al.
Publicado: (2017)

Agalsidase alfa (Replagal(™)) in the treatment of Anderson-Fabry disease
por: Pastores, Gregory M
Publicado: (2007)

Update on role of agalsidase alfa in management of Fabry disease
por: Ramaswami, Uma
Publicado: (2011)

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease
por: Goláň, Lubor, et al.
Publicado: (2015)

An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy
por: Goker-Alpan, Ozlem, et al.
Publicado: (2016)

Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age
por: Parini, Rossella, et al.
Publicado: (2020)

Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
por: Germain, Dominique P, et al.
Publicado: (2015)

The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process
por: Khan, Aneal, et al.
Publicado: (2021)

Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
por: Tsuboi, Kazuya, et al.
Publicado: (2012)

CORRIGENDUM: Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
Publicado: (2012)

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered
por: Ortiz, Alberto, et al.
Publicado: (2015)

Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease
por: Cybulla, Markus, et al.
Publicado: (2022)

Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study
por: Schiffmann, Raphael, et al.
Publicado: (2014)

Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis
por: Hughes, Derralynn, et al.
Publicado: (2021)

Letter concerning “Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha”, by Tanaka et al.
por: Linthorst, Gabor E., et al.
Publicado: (2010)

Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg
por: Vedder, Anouk C., et al.
Publicado: (2007)

Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α
por: Tsuboi, Kazuya, et al.
Publicado: (2014)

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients
por: Smid, Bouwien E, et al.
Publicado: (2011)

One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency
por: Diaz, George A., et al.
Publicado: (2022)

Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
por: Linhart, Aleš, et al.
Publicado: (2023)

Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
por: Ortiz, Alberto, et al.
Publicado: (2016)

Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation
por: Warnock, David G., et al.
Publicado: (2012)

Erratum: Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
Publicado: (2023)

Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation
por: van Kuilenburg, André B. P., et al.
Publicado: (2023)

Erratum to: Screening of Fabry disease in patients with chronic kidney disease in Japan
por: Nagata, Akiko, et al.
Publicado: (2021)

Evaluating enzyme replacement therapies for Anderson-Fabry disease: commentary on a recent report
por: Giugliani, Roberto, et al.
Publicado: (2018)

Erratum: Measuring the Complex Optical Conductivity of Graphene by Fabry-Pérot Reflectance Spectroscopy
por: Ghamsari, Behnood G., et al.
Publicado: (2017)

Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy
por: Warnock, David G, et al.
Publicado: (2015)

Erratum to: Pain management strategies for neuropathic pain in Fabry disease - a systematic review
por: Schuller, Y., et al.
Publicado: (2016)

Fabry disease in children and the effects of enzyme replacement treatment
por: Pintos-Morell, Guillem, et al.
Publicado: (2009)

Erratum in: Will AI Replace Ophthalmologists?
Publicado: (2021)

Erratum to: Relapsing Minimal Change Disease Superimposed on Late-Onset p.N215S Fabry Nephropathy
por: Salerno, Fabio R, et al.
Publicado: (2022)

Clinical features and enzyme replacement therapy in 10 children with Fabry disease
por: Li, Qian, et al.
Publicado: (2023)

Reduction of agalsidase beta infusion time in patients with fabry disease: A case series report and suggested protocol
por: Sánchez-Purificación, Aquilino, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e88n5gm9fvun4t1ev1r0s7pi5h